Nuo Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2015
Filed with the SEC on Nov 13, 2015 and accepted by EDGAR at Nov 12, 2015, 20:45 ET.
Management's discussion and analysis
As filed, 83,093 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and related notes appearing elsewhere in this quarterly report for the period ended September 30, 2015 on Form 10-Q, and our Annual Report for the year ended December 31, 2014 on Form 10-K, filed with the U.S. Securities and Exchange Commission, or the Commission.
Special Note Regarding Forward Looking Statements
Some of the information in this quarterly report for the quarterly period ended September 30, 2015 on Form 10-Q (including the section regarding Management’s Discussion and Analysis of Financial Condition and Results of Operations) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance, or achievements, and may contain the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “the facts suggest,” “will be,” “will continue,” “will likely result” and words of similar import. These statements reflect the Company’s current view of future events and are subject to certain risks and uncertainties as noted in this Annual Report and in other reports filed by us with the Securities and Exchange Commission. The risks and uncertainties are detailed from time to time in reports filed by us with the Securities and Exchange Commission, including Forms 8-K, 10-Q, and 10-K, and include, among others, the following: our limited sources of working capital; our need for substantial additional financing; our history of losses and future expectations; our short history and limited operating experience; our ability to comply with requirements imposed upon us by certain financing agreements, including from Deerfield Management Company, L.P., or Deerfield; our ability to implement our Realignment Plan; our receipt of a gross royalty stream pursuant to the amended and restated license agreement; that our receipt of a gross royalty stream pursuant to the amended and restated license agreement with Arthrex will offer us a more predictable and valuable royalty stream over the life of that agreement; that Deerfield, or anyone else, will provide ongoing capital support; that Deerfield will agree to restructure our existing credit facility; whether the lenders under the Deerfield Facility Agreement may declare an event of default under the agreement and foreclose on our assets; the risk of substantial dilution to the ownership interests of holders of our common stock that may result from a further modification of the Deerfield Facility Agreement; the risk that our common stock becomes devalued as a result of a dilutive event related to the Deerfield Facility Agreement; our ability to successfully implement the amended and restated license agreement with Arthrex; whether CMS will continue to consider its treatment of the geometric mean cost of the services underlying Aurix to be comparable to the geometric mean cost of APC 5054 in the future; our ability to maintain classification of Aurix as APC 5054 and continue to be reimbursed at a profitable national average rate per application in the future; the liquidity of our common stock resulting from its trading on the OTC Markets Group OTCQX marketplace; our reliance on several single source suppliers; our ability to secure additional debt or equity financing; our ability to protect our intellectual property; our compliance with governmental regulations; the success of our clinical trials; our ability to contract with healthcare providers; our ability to successfully sell and market the Aurix System; our ability to secure Medicare reimbursements at adequate levels; the acceptance of our products by the medical community; our ability to source raw materials at affordable costs; our ability to attract and retain key personnel; our ability to successfully pursue strategic collaborations to help develop, support or commercialize our products; and the volatility of our stock price. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements.
In addition to the risks identified under the heading “Risk Factors” in the filings referenced above, other sections of this report may include additional factors which could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on our business, or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.
Finally, we can offer no assurances that we have correctly estimated the resources necessary to execute under our existing customer agreements and seek partners, co-developers or acquirers for our regenerative therapies under the Realignment Plan. If a larger workforce or one with a different skillset is ultimately required to implement the Realignment Plan successfully, or if we inaccurately estimated the cash and cash equivalents necessary to finance our operations into January 2016, or if we are unable to identify additional sources of capital in the near term to continue our operations beyond January 2016, our business, results of operations, financial condition and cash flows may be materially and adversely affected.
The Company undertakes no obligation and does not intend to update, revise or otherwise publicly release any revisions to its forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events.
Corporate Overview
Nuo Therapeutics is a regenerative therapies company developing and marketing products within the U.S. and internationally. We commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The use of autologous (from self) biological therapies for tissue repair and regeneration is part of a transformative clinical strategy designed to improve long term recovery in complex chronic conditions with significant unmet medical needs.
Our current commercial offerings consist of point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. Today, we have two distinct PRP devices, the Aurix System for wound care and the Angel cPRP system for orthopedics markets. Our product sales are predominantly (approximately 84%) in the U.S., where we sell our products through direct sales representatives and our Arthrex Distributor and License Agreement. Growth drivers in the U.S. include the treatment of chronic wounds with Aurix in the Veterans Affairs healthcare system and the Medicare population under a National Coverage Determination when registry data is collected under CMS’ Coverage with Evidence Development (CED) program, and a worldwide distribution and licensing agreement that allows our partner to promote the Angel system for uses other than wound care.
The Aurix TM System
In October 2014, we relaunched our AutoloGel chronic wound care system under the Aurix brand, as a part of our marketing plan for the commercialization of Aurix in the U.S. chronic wound care market.
The Aurix System is a point of care device for the production of a platelet based bioactive wound treatment derived from a small sample of the patient’s own blood. Aurix is cleared by the FDA for use on exuding wounds and is currently marketed in the chronic wound market. Chronic wounds account for an estimated $6 billion to $15 billion annually in U.S. health care costs. The most significant growth driver for Aurix is the 2012 NCD from the CMS which reversed a twenty year old non-coverage decision for autologous blood products used in wound care. Using the patient’s own platelets as a therapeutic agent, Aurix harnesses the body’s natural healing processes to deliver growth factors, chemokines and cytokines known to promote angiogenesis and to regulate cell growth and the formation of new tissue. Once applied to the prepared wound bed, the biologically active platelet gel can restore the balance in the wound environment to transform a non-healing wound to a wound that heals naturally. There have been nine peer-reviewed scientific and clinical publications demonstrating the effectiveness of Aurix in the management of chronic wounds since the device and gel was cleared by the FDA in 2007.
CMS previously advised us that payment levels for reimbursement claims with respect to Aurix would be reviewed annually and subject to change. Revisions to decrease payment rates for reimbursement claims are likely to negatively impact the Company's economic value proposition of Aurix in the market for advanced wound care therapies. On July 1, 2015, CMS released the proposed Hospital Outpatient Prospective Payment System (HOPPS) rule for calendar year 2016. CMS had proposed an average national payment of $305.10. This represented a decrease from the effective HOPPS proposed average payment in prior periods, as the national average rate was $411 per treatment during the 2014 calendar year, and $430 per treatment in 2015. The Company worked with CMS and experts in the field, to establish a reasonable payment in the final rule for 2016. The Aurix™ System reimbursement rate under the Hospital Outpatient Prospective Payment System (HOPPS) for the calendar year 2016 has been published by the Centers for Medicare and Medicaid Services (CMS). Aurix was placed in Ambulatory Payment Classification (APC) 5054 (Level 4 Skin Procedures) and will be reimbursed at a national average rate of $1,411 per application effective January 1, 2016. In the text of the ruling, CMS commented they believe the geometric mean cost of the services underlying Aurix is comparable to the geometric mean cost of APC 5054.
The Company’s Aurix revenues in VA facilities are unaffected by CMS determined reimbursement rates, as the Company establishes a price on the Federal Supply Schedule.
In September 2009, we entered into a license and distribution agreement with Millennia Holdings, Inc. (“Millennia”) for the Company’s Aurix System in Japan. Since then, Millennia has been collecting and publishing clinical data for regulatory purposes and expanding the utilization of Aurix throughout their network. The diabetic population in Japan is estimated to be approximately seven million adults. Millennia has assisted the Company in securing a partner to address widespread distribution in Japan.
In January 2015, we granted to Rohto a royalty bearing, nontransferable, exclusive license, with limited right to sublicense, to use certain of the Company’s intellectual property for the development, import, use, manufacturing, marketing, sale and distribution for all wound care and topical dermatology applications of the Aurix system and related intellectual property and know-how in human and veterinary medicine in Japan in exchange for an upfront payment from Rohto of $3.0 million. The agreement also contemplates additional royalty payments based on the net sales of Aurix in Japan and an additional future cash payment in the event specific milestones are met.
In connection with and effective as of the entering into the Rohto Agreement, we executed Amendment No. 5 to the Licensing and Distribution Agreement with Millennia dated September 10, 2009, as subsequently amended to terminate the Millennia Agreement and to allow us to transfer the exclusivity rights from Millennia to Rohto. In connection with this amendment we paid a one-time, non-refundable fee of $1.5 million to Millennia upon our receipt of the $3.0 million upfront payment from Rohto and may be required to pay certain future royalty payments to Millennia based upon net sales in Japan. Millennia has been instrumental in establishing the advanced wound care market in Japan, and will continue to work with Rohto to develop the market for Aurix. Further, Rohto has assumed all responsibility for securing the MA from Japan’s MHLW, while we will provide relevant product information, as well as clinical and other data to support Rohto’s MA application.
Angel Product Line
The Angel cPRP System, acquired from Sorin Group USA, Inc. in April 2010, is designed for single-patient use at the point of care, and provides a simple, and flexible means for producing quality PRP and PPP from whole blood or bone marrow. The Angel cPRP System is a multi-functional cell separation device which produces cPRP for use in the operating room and clinic and is used in a range of orthopedic and cardiovascular indications. The Angel System is a point of care device for the production of a concentrated, aseptic platelet-based bioactive therapy derived from a small sample of the patient’s own blood.
In August 2013, we entered into a Distributor and License Agreement with Arthrex. Under the terms of this agreement, Arthrex obtained the exclusive rights to sell, distribute, and service our Angel Concentrated Platelet System and activAT throughout the world for all uses other than chronic wound care. We granted Arthrex a limited license to use our intellectual property as part of enabling Arthrex to sell these products. Arthrex purchases these products from us to distribute and service. Arthrex pays us a certain royalty rate based upon volume of the products sold. The exclusive nature of Arthrex’s rights to sell, distribute and service the products is subject to certain existing supply and distribution agreements such that Arthrex may instruct us to terminate or not renew any of such agreements. In addition, Arthrex’s rights to sell, distribute and service the products is not exclusive in the non-surgical dermal and non-surgical aesthetics markets. On October 16, 2015, the Company entered into an Amended and Restated License Agreement (the "Amended Arthrex Agreement") with Arthrex, which amended and restated the Original Arthrex Agreement Under the terms of the Amended Arthrex Agreement, among others, the Company licensed certain exclusive and non-exclusive rights to Arthrex, for which it will receive certain royalties through 2021, and on a date to be determined by Arthrex, but not later than March 31, 2016, Arthrex will assume all rights related to the manufacture and supply of the Angel product line. As part of the transaction, the Company transferred to Arthrex all of its rights and title to product registration rights and intellectual property (other than patents) related to Angel. In connection with the Agreement, senior lien holders Deerfield Special Situations Fund, L.P., Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P. irrevocably released their liens on the product registration rights and intellectual property (other than patents) assets transferred by the Company to Arthrex (See Note 10 – Subsequent Events for additional details.)
ALDHbr, or Bright Cell, Technology and Development Pipeline
We acquired the ALDHbr “Bright Cell” technology as part of our acquisition of Aldagen in February 2012. The Bright Cell technology is a novel approach to cell-based regenerative medicine with potential clinical indications in large markets with significant unmet medical needs, such as peripheral arterial disease and ischemic stroke. The Bright Cell technology is unique in that it utilizes an intracellular enzyme marker to facilitate fractionation of essential regenerative cells from a patient’s bone marrow. This core technology was originally licensed by Aldagen from Duke University and Johns Hopkins University. The proprietary bone-marrow fractionation process identifies and isolates active stem and progenitor cells expressing high levels of the enzyme aldehyde dehydrogenase, or ALDH, which is a key enzyme involved in the regulation of gene activities associated with cell proliferation and differentiation. These autologous, selected biologically instructive cells have the potential to promote the repair and regeneration of multiple types of cells and tissues, including the growth of new blood vessels, or angiogenesis, which is critical to the generation of healthy tissue.
Reorganization of Research and Development Operations related to ALD-401
In September 2013, we announced our decision to begin a strategic reorganization of our research and development operations that involved discontinuing clinical trials of ALD-401, which focused on the RECOVER-Stroke trial and one component of the technology present in the ALDH Bright Cell platform. This discontinuation was limited to the above mentioned clinical trial of RECOVER-Stroke, and does not represent our discontinuation of efforts to develop and commercialize Bright Cell technology. Following the January 2014 completion of the trial enrollment in the RECOVER-Stroke trial, in May 2014 we announced preliminary efficacy and safety results of our RECOVER-Stroke Phase 2 clinical trial in patients with neurological damage arising from ischemic stroke and treated with ALD-401. Observed improvements in the primary endpoint (mean modified Rankin Score or mRS) of the trial were not clinically or statistically significant. In light of this outcome, we discontinued further funding of the ALD-401 development program, and in connection therewith, closed our R&D facility in Durham, NC, which supported the development of ALD-401. This 2014 decision to close down the facility was in line with the overall realignment of our commercial operations to focus on the wound care market.
Continued Development of Bright Cell Technology
Notwithstanding the discontinuation of further funding of the RECOVER-Stroke clinical trials, we will continue to develop the Bright Cell technology platform for other uses, and will conduct a Phase 1/2 clinical trial in critical limb ischemia (PACE), that is being funded by the National Institutes of Health, and a Phase 1 clinical trial in grade IV malignant glioma following surgery, that is funded by Duke University.
Recent Events
At September 30, 2015 we had total debt outstanding under the Deerfield Facility Agreement of $37.6 million, including accrued interest. Pursuant to the terms of the Deerfield Facility Agreement, we are required to maintain a compensating cash balance of $5.0 million in deposit accounts subject to control agreements in favor of the lenders. As of September 30, 2015, we had approximately $4.1 million in cash and cash equivalents and we were not in compliance with that covenant. The terms of the Deerfield Facility Agreement also required us to pay Deerfield the accrued interest amount of approximately $2.6 million on October 1, 2015, which we were unable to do. In addition, because our revenue for the three month period ended September 30, 2015 was less than the net sales threshold contemplated in the Deerfield Facility Agreement, Deerfield has the option of requiring us to prepay on March 31, 2016, an amount equal to one-third of the aggregate amount of the credit facility together with accrued and unpaid interest thereon. On November 11, 2015, we entered into a letter agreement with Deerfield and certain of its affiliates pursuant to which the Deerfield Facility Agreement was modified to provide that, (i) between November 11, 2015 and December 4, 2015, the amount of cash that is required to be maintained in a deposit account subject to control agreements in favor of our senior lenders was reduced from $5,000,000 to $1,750,000 and (ii) the date for payment of the accrued interest amount originally payable on October 1, 2015 was extended to December 4, 2015. We believe the modification agreement will allow us to continue our substantive discussions with the lenders to reduce our risk of default, thereby permitting us to continue our operations, but we can provide no assurance that we will be successful in this effort. We cannot provide any assurance that the lenders will agree to modify the Deerfield Facility Agreement, whether any proposed modifications to the agreement would be on terms favorable, or acceptable, to us, or whether the lenders will declare an event of default under the agreement and foreclose on our assets by enforcing their rights under our agreements with them. If we cannot agree on additional modifications to the Deerfield Facility Agreement, we may be required to curtail or cease operations or, alternatively, seek court supervised protection from creditor claims. Even if we can reach an agreement to further modify the Deerfield Facility Agreement in a manner that is acceptable to us, management believes that we will be required to identify additional sources of capital in the near term to continue our operations beyond January 2016. Any additional agreement that we reach with the lenders under the Deerfield Facility Agreement is expected to involve substantial dilution to the ownership interests of holders of our common stock, and could involve other conditions causing the value of our common stock to decline.
Because of recent events, including a substantial reduction in our stock price and our situation under the Deerfield Facility Agreement and liquidity situation, we determined that it was more likely than not that the fair value of our single reporting unit was reduced below the carrying value of its net equity, requiring an impairment test as of September 30, 2015. We compared the carrying value of our single reporting unit to its fair value and concluded the carrying value of the unit exceeded its fair value. We then performed the second step of the goodwill impairment test and determined that our goodwill was impaired. As a result, we recognized a non-cash goodwill impairment charge of approximately $1.1 million to write-down the goodwill to its estimated fair value as of September 30, 2015.
Additionally, there were triggering events identified during the three months ended September 30, 2015 indicating that our IPR&D asset may be impaired and, as a result, we performed an impairment test as of September 30, 2015. In connection with determining the fair value of our goodwill associated with our reporting unit, we determined the fair value of our one reporting unit based on our market capitalization as of September 30, 2015 (see “Goodwill”). Based on that fair value, we determined that our IPR&D asset was impaired as of September 30, 2015 and recognized a non-cash IPR&D impairment charge of approximately $22.6 million during the three month period ended September 30, 2015.
We had cash and cash equivalents on hand at September 30, 2015 of approximately $4.1 million. Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history and uncertainty of future profitability and possible fluctuations in financial results. The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe that our current resources, expected revenue from current products, royalty revenue and license fees will be inadequate to maintain our operations beyond January 2016. Management believes the going-concern basis is appropriate for the accompanying condensed consolidated financial statements, however our inability to negotiate modifications to the existing Deerfield Facility Agreement that are favorable to us may create substantial doubt regarding our ability to continue as a going concern.
Results of Operations
Our revenues will be insufficient to cover our operating expenses in the near term. Operating expenses primarily consist of employee compensation, professional fees, consulting expenses, clinical trial costs, and other general business expenses such as insurance, travel related expenses, and sales and marketing related items. We expect our operating expenses, excluding impairment charges, to decrease as a result of our realignment plan. We have realigned our operational and commercial activities to reduce costs and refocus our efforts on the commercial wound care market. However, we expect losses to continue for the foreseeable future.
Comparison of Operating Results for the Three-Month Period Ended September 30, 2015 and 2014
Revenue and Gross Profit
Revenues increased $477,000 (28%) to $2,169,000 comparing the three months ended September 30, 2015 to the previous year. This was due to an increase in product sales related to Angel of $338,000 and Aurix $94,000 and Angel royalties of $59,000.
Overall gross profit increased $211,000 (59%) to $569,000 and overall gross margin increased to 26% from 21%, comparing the three months ended September 30, 2015 to the previous year. The increase in gross profit resulted from the increase in Aurix product sales and an increase in Angel related royalties and reduced charges for Angel machine refurbishment costs.
The following table discloses the profitability of sales, license fees and royalties:
| Three Months Ended September 30, Aurix 2015 | 2014 | Angel 2015 | 2014 | Bright Cell 2015 | 2014 | Total 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|
| Product sales | $188,000 | $94,000 | $1,445,000 | $1,107,000 | $- | $- | $1,633,000 | $1,201,000 |
| License Fees | - | - | 101,000 | 100,000 | - | - | 101,000 | 100,000 |
| Royalties | - | - | 392,000 | 333,000 | 43,000 | 58,000 | 435,000 | 391,000 |
| Total revenue | 188,000 | 94,000 | 1,938,000 | 1,540,000 | 43,000 | 58,000 | 2,169,000 | 1,692,000 |
| Product cost of sales | 122,000 | 92,000 | 1,435,000 | 1,198,000 | - | - | 1,557,000 | 1,290,000 |
| Royalty cost of sales | - | - | 40,000 | 39,000 | 3,000 | 5,000 | 43,000 | 44,000 |
| Total cost of revenue | 122,000 | 92,000 | 1,475,000 | 1,237,000 | 3,000 | 5,000 | 1,600,000 | 1,334,000 |
| Gross profit/(loss) | 66,000 | 2,000 | 463,000 | 303,000 | 40,000 | 53,000 | 569,000 | 358,000 |
| Gross margin | 35% | 2% | 24% | 20% | 93% | 91% | 26% | 21% |
Aurix Revenue and Gross Profit
Aurix product sales increased $94,000 while gross profit increased $64,000 comparing the three months ended September 30, 2015 to the previous year. The increase in gross profit and gross margin was due to increased product sales.
Angel Revenue and Gross Profit
Overall Angel revenue increased $398,000 while gross profit increased $160,000 comparing the three months ended September 30, 2015 to the previous year. Product sales increased by $338,000 due to higher sales of both centrifuges and disposables. The increase in gross profit and gross margin was primarily due to lower centrifuge warranty repair expenses and higher royalty revenue.
Under the terms of the Amended Arthrex Agreement, Arthrex will assume manufacturing and supply responsibilities for the Angel product line at a date to be determined by Arthrex, but not later than March 31, 2016. Once fully transitioned, the Company will no longer reflect revenue related to Angel product sales and product cost of sales, only the related Angel royalties, will be reflected in the condensed consolidated statements of operations.
Operating Expenses
Operating expenses increased $22,973,000 (473%) to $27,828,000 comparing the three months ended September 30, 2015 to the same period last year. A discussion of the various components of operating expenses follows.
Sales and Marketing
Sales and marketing increased $346,000 (28%) to $1,583,000 comparing the three months ended September 30, 2015 to the previous year. The increase was primarily due to the planned expansion of our commercial and marketing organization that began in the second quarter of 2014 and costs associated with the reorganization of the company.
Research and Development
Research and development expenses decreased $493,000 (49%) to $515,000 comparing the three months ended September 30, 2015 to the previous year. The decrease was primarily due to lower CED costs related to the development of Aurix CED protocols.
General and Administrative
General and administrative expenses decreased $622,000 (24%) to $1,989,000 comparing the three months ended September 30, 2015 to the previous year. The decrease was primarily due to lower compensation expense related to the recent realignment of the Company, and lower expense related to the closure of our Durham, North Carolina facility in 2014. This was partially offset by increased severance costs related to the recent realignment of the company.
Impairment of Intangible Assets
Because of recent events, including a substantial reduction in our stock price through the period ending September 30, 2015 and our situation under the Deerfield Facility Agreement and liquidity situation, we determined that it was more likely than not that the fair value of our single reporting unit was reduced below the carrying value of its net equity, requiring an impairment test as of September 30, 2015. We compared the carrying value of our single reporting unit to its fair value and concluded the carrying value of the unit exceeded its fair value. We then performed the second step of the goodwill impairment test and determined that our goodwill was impaired. As a result, we recognized a non-cash goodwill impairment charge of approximately $1.1 million to write-down the goodwill to its estimated fair value as of September 30, 2015.
Additionally, there were triggering events identified during the three months ended September 30, 2015 indicating that our IPR&D asset may be impaired and, as a result, we performed an impairment test as of September 30, 2015. In connection with determining the fair value of our goodwill associated with our reporting unit, we determined the fair value of our one reporting unit based on our market capitalization as of September 30, 2015 (see “Goodwill” above). Based on that fair value, we determined that our IPR&D asset was impaired as of September 30, 2015 and recognized a non-cash IPR&D impairment charge of approximately $22.6 million during the three month period ended September 30, 2015. We will continue to develop the IPR&D Bright Cell technology platform for other uses, and will conduct a Phase 1/2 clinical trial in critical limb ischemia (PACE), that is being funded by the National Institutes of Health, and a Phase 1 clinical trial in grade IV malignant glioma following surgery, that is funded by Duke University.
Other Income and Expense
Other expense, net decreased $13,718,000 (4836%) to other income, net of $13,435,000 comparing the three months ended September 30, 2015 to the same period last year. The difference was primarily due to the $13,857,000 change in the fair value of derivative liabilities from an unrealized gain of $543,000 to an unrealized gain of $14,400,000 for the three months ended September 30, 2014 and 2015, respectively partially offset by an increase in interest expense under the Deerfield Facility Agreement executed on March 31, 2014.
Comparison of Operating Results for the Nine-Month Period Ended September 30, 2015 and 2014
Revenue and Gross Profit
Revenues increased $4,038,000 (69%) to $9,902,000, comparing the nine months ended September 30, 2015 to the previous year. This was primarily due to an increase in license fee revenue of $3,000,000, related to the Rohto agreement, and Angel product sales and royalties of $757,000 and $267,000, respectively.
Overall gross profit increased $1,915,000 (162%) to $3,094,000 while overall gross margin increased to 31% from 20%, comparing the nine months ended September 30, 2015 to the previous year. The increase in gross margin resulted primarily from the Rohto license fees of $3,000,000 and costs of license fees paid to Millennia of $1,500,000, as well as increased royalties.
The following table discloses the profitability of sales, license fees and royalties:
| Nine Months Ended September 30, Aurix 2015 | 2014 | Angel 2015 | 2014 | Bright Cell 2015 | 2014 | Total 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|
| Product sales | $419,000 | $379,000 | $4,853,000 | $4,096,000 | $- | $- | $5,272,000 | $4,475,000 |
| License Fees | 3,000,000 | - | 302,000 | 302,000 | - | - | 3,302,000 | 302,000 |
| Royalties | - | - | 1,169,000 | 902,000 | 159,000 | 185,000 | 1,328,000 | 1,087,000 |
| Total revenue | 3,419,000 | 379,000 | 6,324,000 | 5,300,000 | 159,000 | 185,000 | 9,902,000 | 5,864,000 |
| Product cost of sales | 341,000 | 271,000 | 4,836,000 | 4,281,000 | - | - | 5,177,000 | 4,552,000 |
| License fees cost of sales | 1,500,000 | - | - | - | - | - | 1,500,000 | - |
| Royalty cost of sales | - | - | 117,000 | 118,000 | 13,000 | 15,000 | 130,000 | 133,000 |
| Total cost of revenue | 1,841,000 | 271,000 | 4,953,000 | 4,399,000 | 13,000 | 15,000 | 6,807,000 | 4,685,000 |
| Gross profit/(Loss) | 1,578,000 | 108,000 | 1,371,000 | 901,000 | 146,000 | 170,000 | 3,095,000 | 1,179,000 |
| Gross margin | 46% | 28% | 22% | 17% | 92% | 92% | 31% | 20% |
Aurix Revenue and Gross Profit
Overall, Aurix revenue increased $3,040,000 while gross profit increased $1,470,000 comparing the nine months ended September 30, 2015 to the previous year. Increased sales and gross profit was primarily due to the $3,000,000 license fee related to the Rohto agreement and related costs of license fees paid to Millennia of $1,500,000. Aurix product sales increased by $40,000 while gross profit from these sales decreased $30,000. The decrease in gross profit and gross margin from product sales was primarily due to an increase in costs of sales related to royalty expense for the underlying patents, increase in inventory obsolescence charges, and a temporary increase in the cost of raw materials used in the Aurix kit.
Angel Revenue and Gross Profit
Overall Angel revenue increased $1,024,000 while gross profit increased $470,000 comparing the nine months ended September 30, 2015 to the previous year. Product sales increased $757,000 as a result of higher centrifuge sales partially offset by lower disposable sales. The increase in gross profit and gross margin was primarily due to an increase in royalties along with lower centrifuge warranty repair and logistics expenses. Under the terms of the Amended Arthrex Agreement, Arthrex will assume manufacturing and supply responsibilities for the Angel product line at a date to be determined by Arthrex, but not later than March 31, 2016. Once fully transitioned the Company will no longer reflect revenue related to Angel product sales and product cost of sales, only the related Angel royalties, will be reflected in the Condensed Consolidated Statements of Operations.
Operating Expenses
Operating expenses increased $18,012,000 (89%) to $38,161,000 comparing the nine months ended September 30, 2015 to the same period last year. A discussion of the various components of operating expenses follows below.
Sales and Marketing
Sales and marketing increased $1,275,000 (33%) to $5,188,000 comparing the nine months ended September 30, 2015 to the previous year. The increase was primarily due to the planned expansion of our commercial and marketing organization that began in the second quarter of 2014. The growth of the commercial organization led to increased employee compensation and travel expenses which was partially offset by reduced consulting and external marketing costs.
Research and Development
Research and development expenses decreased $1,908,000 (51%) to $1,847,000 comparing the nine months ended September 30, 2015 to the previous year. The decrease was primarily due to lower clinical trial costs as a result of the discontinuation of the ALD-401 clinical trial in 2014 and reduced external CED costs related to the development of Aurix CED protocols, partially offset by an increase in employee compensation for the clinical team leading the AU (Gold) study.
General and Administrative
General and administrative expenses decreased $412,000 (5%) to $7,385,000 comparing the nine months ended September 30, 2015 to the previous year. The decrease in expenses is primarily the result of lower compensation expense, including lower expense related to the closure of our Durham, North Carolina facility in 2014, and reduced employee stock-based compensation. This is partially offset by higher severance expense related to the recent realignment of the company along with increased depreciation expense, legal fees, and professional service fees.
Impairment of Intangible Assets
Because of recent events, including a substantial reduction in our stock price and our situation under the Deerfield Facility Agreement and liquidity situation, we determined that it was more likely than not that the fair value of our single reporting unit was reduced below the carrying value of its net equity, requiring an impairment test as of September 30, 2015. We compared the carrying value of our single reporting unit to its fair value and concluded the carrying value of the unit exceeded its fair value. We then performed the second step of the goodwill impairment test and determined that our goodwill was impaired. As a result, we recognized a non-cash goodwill impairment charge of approximately $1.1 million to write-down the goodwill to its estimated fair value as of September 30, 2015.
Additionally, there were triggering events identified during the three months ended September 30, 2015 indicating that our IPR&D asset may be impaired and, as a result, we performed an impairment test as of September 30, 2015. In connection with determining the fair value of our goodwill associated with our reporting unit, we determined the fair value of our one reporting unit based on our market capitalization as of September 30, 2015 (see “Goodwill” above). Based on that fair value, we determined that our IPR&D asset was impaired as of September 30, 2015 and recognized a non-cash IPR&D impairment charge of approximately $22.6 million during the three month period ended September 30, 2015.
As a result of our decision to discontinue further funding of the ALD-401 development program during the nine months ended September 30, 2014, we recognized a non-cash impairment charge of approximately $3.7 million to our IPR&D asset and $1.0 million to our trademarks. We will continue to develop the IPR&D Bright Cell technology platform for other uses, and will conduct a Phase 1/2 clinical trial in critical limb ischemia (PACE), that is being funded by the National Institutes of Health, and a Phase 1 clinical trial in grade IV malignant glioma following surgery, that is funded by Duke University.
Other Income and Expense
Other expense, net decreased $27,244,000 (989%) to other income, net of $24,489,000 comparing the nine months ended September 30, 2015 to the previous year. The difference was primarily due to the $27,408,000 change in the fair value of derivative liabilities from an unrealized loss of $159,000 to an unrealized gain of $27,249,000 for the nine months ended September 30, 2014 and 2015, respectively.
Liquidity and Capital Resources
Since our inception we have incurred, and continue to incur, significant losses from operations. For the nine months ended September 30, 2015, we incurred a loss from operations of approximately $35.1 million and have an accumulated deficit at September 30, 2015 of $120.7 million. At September 30, 2015, we had working capital of approximately $0.4 million.
At September 30, 2015 we had total debt outstanding under the Deerfield Facility Agreement of $37.6 million, including accrued interest. Pursuant to the terms of the Deerfield Facility Agreement, we are required to maintain a compensating cash balance of $5.0 million in deposit accounts subject to control agreements in favor of the lenders. As of September 30, 2015, we had approximately $4.1 million in cash and cash equivalents and were not in compliance with that covenant. The terms of the Deerfield Facility Agreement also required us to pay Deerfield the accrued interest amount of approximately $2.6 million on October 1, 2015, which we were unable to do. In addition, because our revenue for the three month period ended September 30, 2015 was less than the net sales threshold contemplated in the Deerfield Facility Agreement, Deerfield has the option of requiring us to prepay on March 31, 2016, an amount equal to one-third of the aggregate amount of the credit facility together with accrued and unpaid interest thereon. On November 11, 2015, we entered into a letter agreement with Deerfield and certain of its affiliates pursuant to which the Deerfield Facility Agreement was modified to provide that, (i) between November 11, 2015 and December 4, 2015, the amount of cash that is required to be maintained in a deposit account subject to control agreements in favor of our senior lenders was reduced from $5,000,000 to $1,750,000 and (ii) the date for payment of the accrued interest amount originally payable on October 1, 2015 was extended to December 4, 2015. We believe the modification agreement will allow us to continue our substantive discussions with the lenders to reduce our risk of default, thereby permitting us to continue our operations, but we can provide no assurance that we will be successful in this effort. We cannot provide any assurance that the lenders will agree to modify the Deerfield Facility Agreement, whether any proposed modifications to the agreement would be on terms favorable, or acceptable, to us, or whether the lenders will declare an event of default under the agreement and foreclose on our assets by enforcing their rights under our agreements with them. If we cannot agree on additional modifications to the Deerfield Facility Agreement, we may be required to curtail or cease operations or, alternatively, seek court supervised protection from creditor claims. Even if we can reach an agreement to further modify the Deerfield Facility Agreement in a manner that is acceptable to us, management believes that we will be required to identify additional sources of capital in the near term to continue our operations beyond January 2016. Any additional agreement that we reach with the lenders under the Deerfield Facility Agreement is expected to involve substantial dilution to the ownership interests of holders of our common stock, and could involve other conditions causing the value of our common stock to decline.
We had cash and cash equivalents on hand at September 30, 2015 of approximately $4.1 million. Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, lack of operating history and uncertainty of future profitability and possible fluctuations in financial results. The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due.
We believe that our current resources, expected revenue from current products, royalty revenue and license fees will be adequate to maintain our operations into January 2016. Management believes the going-concern basis is appropriate for the accompanying condensed consolidated financial statements, however our inability to negotiate modifications to the existing Deerfield Facility Agreement that are favorable to us will create substantial doubt regarding our ability to continue as a going concern. If we are unable to increase our revenues as much as expected or if capital infusions are not available to the Company from future strategic partnerships, from the sale of shares under the purchase agreements we entered into with Lincoln Park, or through the sale of debt, equity and equity-linked securities, licensing, or royalty arrangements, then we may be required to curtail portions of our strategic plan or to cease operations. Specific programs that may require additional funding include, without limitation, continued investment in the sales, marketing, distribution, and customer service areas, further expansion into the international markets, significant new product development or modifications, and pursuit of other opportunities. If adequate capital cannot be obtained on a timely basis and on satisfactory terms, the Company’s operations could be materially negatively impacted.
Historically, we have financed our operations by raising debt, issuing equity and equity-linked instruments, executing licensing arrangements, and to a lesser extent by generating royalties and product revenues. In 2014, we raised approximately $36.7 million, net from the issuance of convertible debt and warrants and the sale of common stock and warrants. We used approximately $6.2 million of the proceeds from these transactions to retire outstanding debt and accrued interest in 2014, and we converted approximately $3.1 million of previously outstanding convertible debt and interest into common stock. We have incurred, and continue to incur, recurring losses and negative cash flows. If we continue to incur negative cash flow from sources of operating activities for longer than expected, even if we reach agreement with Deerfield our ability to continue as a going concern could be in substantial doubt and we will require additional funds through debt facilities, and/or public or private equity or debt financings to continue operations. We cannot provide any assurance that we will be able to obtain the capital we require on a timely basis or on terms acceptable to us.
In January 2015 we granted to Rohto Pharmaceutical Co., Ltd. a royalty bearing, nontransferable, exclusive license, with limited right to sublicense, to use certain of the Company’s intellectual property for the development, import, use, manufacturing, marketing, sale and distribution for all wound care and topical dermatology applications of the Aurix system and related intellectual property and know-how in human and veterinary medicine in Japan in exchange for an upfront payment from Rohto of $3.0 million. In connection with and effective as of the entering into the Rohto Agreement, we executed Amendment No. 5 to the Licensing and Distribution Agreement with Millennia dated September 10, 2009, as subsequently amended to terminate the Millennia Agreement and to allow us to transfer the exclusivity rights from Millennia to Rohto. In connection with this amendment we paid a one-time, non-refundable fee of $1.5 million to Millennia upon our receipt of the $3.0 million upfront payment from Rohto to Millennia.
The Company will continue to pursue exploratory conversations with companies regarding their interest in our various products and technologies. We will seek to leverage these relationships if and when they materialize to secure non-dilutive sources of funding. There is no assurance that we will be able to secure such relationships or, even if we do, the terms will be favorable to us.
On August 11, 2015, our Board of Directors approved our Realignment Plan with the goal of preserving and maximizing, for the benefit of our stockholders, the value of our existing assets. The plan eliminated approximately 30% of our workforce and was aimed at the preservation of cash and cash equivalents to finance our future operations and support our revised business objectives. We intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our regenerative therapies and continue to execute under our existing agreements with our customers. In connection, with the Realignment Plan, Martin P. Rosendale, stepped down as Chief Executive officer effective August 14, 2015, and continues to serve us as a consultant on an as needed basis. Effective August 15, 2015, Dean Tozer was appointed as our President and Chief Executive Officer. Immediately prior to such appointment, Mr. Tozer served as our Chief Commercial Officer. We recognized severance costs to executives and non-executives in connection with the Realignment Plan of approximately $0.80 million. All such severance expenses are expected to be paid by the end of the first quarter of 2016.
We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our regenerative therapies or execute under our customer agreements. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of our existing regenerative therapy assets. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations. If revenues from our customers are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to successfully negotiate modifications to our current Deerfield Facility Agreement and secure additional capital to support our revised business objectives, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.
Net cash provided by (used in) operating, investing, and financing activities for the nine months ended September 30, 2015 and 2014 were as follows:
(in millions)
| September 30, 2015 | September 30, 2014 | |
|---|---|---|
| Cash flows used in operating activities | $(11.7) | $(13.6) |
| Cash flows used in investing activities | $(0.2) | $(0.1) |
| Cash flows provided by financing activities | $— | $30.4 |
Operating Activities
Cash used in operating activities for the nine months ended September 30, 2015 of $11.7 million primarily reflects our net loss of $10.6 million adjusted by a (i) $27.2 million decrease for changes in derivative liabilities resulting from a change in their fair value, (ii) $23.7 million increase for the impairment of goodwill and IPR&D, (iii) $1.2 million increase for amortization of deferred costs and debt discount relating to debt issuances, (iv) $0.7 million increase for stock-based compensation, and (v) $0.5 million increase for depreciation and amortization.
Cash used in operating activities for the nine months ended September 30, 2014 of $13.6 million primarily reflects our net loss of $21.7 million adjusted by a (i) $4.7 million increase for the impairment of trademarks and IPR&D, (ii) $1.4 million increase for amortization of deferred costs and debt discount, (iii) $0.9 million increase for stock-based compensation, (iv) $0.5 million increase for depreciation and amortization, (v) $0.2 million increase for change in derivative liabilities, (vi) $0.2 million increase for a loss on the abandonment of the Aldagen North Carolina lease and (vii) $0.1 million increase for the loss on the disposal of property and equipment.
Investing Activities
Cash used in investing activities for the nine months ended September 30, 2015 primarily reflects the capitalization of CED software configuration costs for data management and the net activity of purchases of Angel centrifuge equipment for research and development purposes and their subsequent sale.
Cash used in investing activities for the nine months ended September 30, 2014 primarily reflects the net activity of purchases and sales of Angel and Aurix™ centrifuge equipment. In addition, we capitalized $0.1 million in business software implementation costs and received $0.1 million from the sale of assets resulting from the closing of our research and development facility related to the ALD-401 clinical trial.
Financing Activities
We did not have any financing activities for the nine months ended September 30, 2015. Net cash provided by financing activities was $30.45 million for the nine months ended September 30, 2014.
For the nine months ended September 30, 2014, we raised $3.7 million through the issuance of common stock and received $35.8 million from convertible debt facilities, both before placement agent fees and offering expenses. This was offset by $2.8 million in debt issuance costs, a $0.3 million cash repayment of a portion of our convertible debt, and a $5.9 million principal balance pay-out of our term loans.
The following provides additional details regarding our cash flows from available financing facilities and activities.
(in millions)
| Nine Months Ended September 30, 2015 | 2014 | |
|---|---|---|
| Proceeds from the issuance of common stock, net | $- | $3.7 |
| Proceeds from the issuance of debt, net | - | 32.9 |
| Debt repayments | - | (6.2) |
| Cash flows provided by financing activities | $- | $30.4 |
33
Issuance of Common Stock
We raised approximately $1.8 million during the six months ended June 30, 2014 from the sale of shares under the purchase agreement entered into with Lincoln Park on February 18, 2013.
On March 31, 2014 we raised $2.0 million, before placement agent’s fees and other offering expenses, from the private placement of 3,846,154 shares of common stock (at a price of $0.52 per share) and five-year stock purchase warrants to purchase 2,884,615 shares of common stock at $0.52 per shares. We paid $0.1 million in placement agent fees and other offering expenses related to this raise.
Debt
On March 31, 2014, we executed the Deerfield Facility Agreement with Deerfield for the issuance of a five-year senior secured convertible credit facility. Under the terms of this agreement, Deerfield agreed to provide to us a convertible credit facility in an amount up to $35 million, before placement agent fees and other offering expenses. We received $9 million in March 2014 and the remaining $26 million in June 2014. We paid approximately $2.7 million in placement agent fees and other offering expenses related to this credit facility in the six months ended June 30, 2014. Prior to November 10, 2015, a technical event of default occurred under this facility.
On November 11, 2015, we entered into a letter agreement with Deerfield and certain of its affiliates pursuant to which the Deerfield Facility Agreement was modified to provide that, (i) between November 11, 2015 and December 4, 2015, the amount of cash that is required to be maintained in a deposit account subject to control agreements in favor of our senior lenders was reduced from $5,000,000 to $1,750,000 and (ii) the date for payment of the accrued interest amount originally payable on October 1, 2015 was extended to December 4, 2015. We believe the modification agreement will allow us to continue our substantive discussions with the lenders to reduce our risk of default, thereby permitting us to continue our operations, but we can provide no assurance that we will be successful in this effort. We cannot provide any assurance that the lenders will agree to modify the Deerfield Facility Agreement, whether any proposed modifications to the agreement would be on terms favorable, or acceptable, to us, or whether the lenders will declare an event of default under the agreement and foreclose on our assets by enforcing their rights under our agreements with them. If we cannot agree on additional modifications to the Deerfield Facility Agreement, we may be required to curtail or cease operations or, alternatively, seek court supervised protection from creditor claims. Even if we can reach an agreement to further modify the Deerfield Facility Agreement in a manner that is acceptable to us, management believes that we will be required to identify additional sources of capital in the near term to continue our operations beyond January 2016. Any additional agreement that we reach with the lenders under the Deerfield Facility Agreement is expected to involve substantial dilution to the ownership interests of holders of our common stock, and could involve other conditions causing the value of our common stock to decline.
On February 19, 2013, we entered into a Credit and Security Agreement with Mid-Cap Financial from which we received $4.5 million on February 27, 2013, before placement agent fees and other offering expenses. On March 31, 2014, we paid the remaining balance of the term loan of approximately $3.8 million.
On November 21, 2013, we executed agreements with certain investors for the subsequent issuance of 10% subordinated convertible notes and stock purchase warrants, for gross proceeds of $3 million, before placement agent fees and other offering expenses. We received $2.25 million of the expected gross proceeds on December 10, 2013. We received $0.75 million of the gross proceeds in February 2014. On March 31, 2014 the holders of the December 2013 convertible bridge notes (except for one holder), agreed to convert their outstanding notes pursuant to its terms, converting into 5,981,859 shares of common stock. The Company repaid, in its entirety, the portion of the debt excluded from the conversion (including interest and prepayment penalties) pursuant to its terms, for a total cash payment of approximately $339,000.
The $2.1 million JP Nevada Trust 12% Note entered into in April 2011 was repaid in full in June 2014.
Inflation
The Company believes that the rates of inflation in recent years have not had a significant impact on its operations.
Off-Balance Sheet Arrangements
The Company does not have any off-balance sheet arrangements.
Contractual Obligations
Our primary office and warehouse facilities are located in Gaithersburg, Maryland, and comprise approximately 12,000 square feet. This facility falls under two leases with monthly rent, including our share of certain annual operating costs and taxes, at approximately $17,000 per month with the leases expiring September 2019. In addition, we also lease approximately 2,100 square feet in Nashville, Tennessee which is being utilized as a commercial operations office. The lease is approximately $4,000 per month excluding our shares of annual operating expenses and expires April 30, 2018.We also lease a 16,300 square foot facility located in Durham, NC. This facility falls under one lease with monthly rent, including our share of certain annual operating costs and taxes, at approximately $20,000 per month with the lease expiring December 31, 2018. Following the discontinuation of funding for our ALD-401 program in May 2014, we have subleased the facility. The sublease rent is approximately $13,000 per month and expires December 31, 2018.
Purchase obligations consist of a commitment to purchase 600 Aurix centrifuges, 200 of which were paid for during the three months ended June 30, 2015. Receipt of the centrifuges is expected to commence during the fourth quarter of 2015, with the remaining 200 units expected to be delivered during the first quarter of 2016. In addition, we have committed to rebranding and enhancing 270 additional Aurix centrifuges with this same supplier. The September 30, 2015 remaining balance to be paid under this commitment was approximately $350,000. Under the terms of our purchase agreement for Angel machines, we provide an upfront deposit for the purchase of the units and pay the remaining balance upon shipment of the units from our manufacturer. We were obligated to purchase 53 Angel machines based on our deposit balance held at our supplier at September 30, 2015. The remaining balance to be paid for these 53 Angel machines as of September 30, 2015 was approximately $280,000. In addition, as of September 30, 2015, we were obligated to purchase a combination of Angel cPRP processing sets and activAT kits from our supplier which were valued at approximately $1,050,000.
Critical Accounting Policies
In preparing our condensed consolidated financial statements, we make estimates and assumptions that can have a significant impact on our consolidated financial position and results of operations. The application of our critical accounting policies requires an evaluation of a number of complex criteria and significant accounting judgments by us. In applying those policies, our management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions. We have identified the following policies as critical to our business operations and the understanding of our consolidated results of operations. For further information on our critical and other accounting policies, (See Note 1 – Business and Summary of Significant Accounting Principles to our unaudited Condensed Consolidated Financial Statements).
Stock-Based Compensation
Under the Company’s 2002 Long Term Incentive Plan (the “LTIP”) and 2013 Equity Incentive Plan (the “EIP”), the Company grants share-based awards, typically in the form of stock options and stock awards, to eligible employees, directors, and service providers to purchase shares of common stock. The fair values of these awards are determined on the dates of grant or issuance and are recognized as expense over the requisite service periods.
The Company estimates the fair value of stock options on the grant issuance date using the Black-Scholes-Merton option-pricing formula. The determination of fair value using this model requires the use of certain estimates and assumptions that affect the reported amount of compensation cost recognized in the Company’s condensed consolidated statements of operations. These include estimates of the expected term of the option, expected volatility of the Company’s stock price, expected dividends and the risk-free interest rate. These estimates and assumptions are highly subjective and may result in materially different amounts should circumstances change and the Company employ different assumptions in future periods.
For stock options, expected volatilities are based on historical volatility of the Company’s stock. Company data was utilized to estimate option exercises and employee terminations within the valuation model for the period ending September 30, 2015 and the year ended December 31, 2014. No cash dividends have ever been declared or paid on the Company’s common stock and currently none is anticipated. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the options.
The Company estimates the fair value of stock awards based on the closing market value of the Company’s stock on the issuance date of the grant. In certain select cases, the Company has issued stock purchase warrants, outside the LTIP, to service providers in exchange for the performance of consulting or other services. These warrants have generally been immediately vested and expense was recognized equal to the fair value of the warrant on the date of grant using the Black-Scholes option pricing model. The same assumptions (and related risks) as discussed above apply, with the exception of the expected term; for warrants issued to service providers, the Company estimates that the warrant will be held for the full term.
Revenue Recognition
The Company recognizes revenue when four basic criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) consideration is fixed or determinable; and (4) collectability is reasonably assured.
Sales of products
We provide for the sale of our products, including disposable processing sets and supplies to customers. Revenue from the sale of products is recognized upon shipment of products to the customers. We do not maintain a reserve for returned products as in the past those returns have not been material and are not expected to be material in the future.
Usage or leasing of blood separation equipment
As a result of the acquisition of the Angel business, we acquired various multiple element revenue arrangements that combined the (i) usage or leasing of blood separation processing equipment, (ii) maintenance of processing equipment, and (iii) purchase of disposable processing sets and supplies. We assigned these multiple element revenue arrangements to Arthrex in 2013 and no longer recognize revenue under these arrangements.
Percentage-based fees on licensee sales of covered products, including those sold by Arthrex, are generally recorded as products are sold by licensees and are reflected as royalties in the condensed consolidated statements of operations. Direct costs associated with product sales and royalty revenues are recorded at the time that revenue is recognized.
Deferred revenue at September 30, 2015 consists of prepaid licensing revenue of approximately $1,140,000 from the licensing of Angel centrifuges and $182,000 from product sales billed and not yet shipped. Prepaid licensing revenue is being recognized on a straight-line basis over the five-year term of the agreement. Deferred revenue related to products billed and not yet shipped will be recognized when the product is shipped to the customer. Revenue of approximately $302,000 related to the prepaid license was recognized during both the nine months ended September 30, 2015 and 2014. In 2013, a medical device excise tax came into effect that required manufacturers to pay tax of 2.3% on the sale of certain medical devices; we report the medical device excise tax on a gross basis, recognizing the tax as both revenue and costs of sales.
License Fees
The Company’s license agreement with Rohto contains multiple elements that include the delivered license and other ancillary performance obligations, such as maintaining its intellectual property and providing regulatory support and training to Rohto. The Company has determined that the ancillary performance obligations are perfunctory and incidental and are expected to be minimal and infrequent. Accordingly, the Company has combined the ancillary performance obligations with the delivered license and is recognizing revenue as a single unit of accounting following revenue recognition guidance applicable to the license. Because the license is delivered, the Company recognized the entire $3.0 million license fee as revenue in the three months ended March 31, 2015. Other elements contained in the license agreement, such as fees and royalties related to the supply and future sale of the product, are contingent and will be recognized as revenue when earned.
Intangible Assets and Goodwill
Intangible assets were acquired as part of our acquisition of the Angel business and Aldagen, and consist of definite-lived and indefinite-lived intangible assets, including goodwill.
Definite-lived intangible assets
Our definite-lived intangible assets include trademarks, technology (including patents) and customer relationships, and are amortized over their useful lives and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, we test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), we would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. We periodically reevaluate the useful lives for these intangible assets to determine whether events and circumstances warrant a revision in their remaining useful lives.
We determined that our definite-lived intangible assets were not impaired as of September 30, 2015. During the three months ended June 30, 2014 we recognized a non-cash impairment charge related to our trademarks of approximately $1.0 million in the three month period ended June 30, 2014. (See Note 4 — Goodwill and Intangible Assets for additional details.)
Indefinite-lived intangible assets
We evaluate our indefinite-lived intangible asset, consisting solely of in-process research and development (“IPR&D”) acquired in the Aldagen acquisition, for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable, and at least on an annual basis on October 1 of each year, by comparing the fair value of the asset with its carrying amount. If the carrying amount of the intangible asset exceeds its fair value, we would recognize an impairment loss in the amount of that excess.
We determined that our IPR&D asset was impaired as of September 30, 2015 and recognized a non-cash IPR&D impairment charge of approximately $22.6 million during the three month period ended September 30, 2015. During the three months ended June 30, 2014 we recognized a non-cash impairment charge related to our IPR&D of approximately $3.7 million. (See Note 4 — Goodwill and Intangible Assets for additional details.)
Goodwill
Goodwill represents the purchase price of acquisitions in excess of the amounts assigned to acquired tangible or intangible assets and assumed liabilities. Goodwill is tax deductible in all relevant jurisdictions. As a result of our acquisition of Aldagen in February 2012, we recorded goodwill of approximately $422,000. Prior to the acquisition of Aldagen, we had goodwill of approximately $707,000 as a result of the acquisition of the Angel business in April 2010. Goodwill is not amortized, but is subject to periodic review for impairment. Goodwill is reviewed annually, as of October 1, and whenever events or changes in circumstances indicate that the carrying amount of the goodwill might not be recoverable. We perform our review of goodwill on our one reporting unit.
Before employing detailed impairment testing methodologies, we first evaluate the likelihood of impairment by considering qualitative factors relevant to our reporting unit. When performing the qualitative assessment, we evaluate events and circumstances that would affect the significant inputs used to determine the fair value of the goodwill. Events and circumstances evaluated include: macroeconomic conditions that could affect us, industry and market considerations for the generic pharmaceutical industry that could affect us, cost factors that could affect our performance, our financial performance (including share price), and consideration of any company-specific events that could negatively affect us, our business, or the fair value of our business. If we determine that it is more likely than not that goodwill is impaired, we will then apply detailed testing methodologies. Otherwise, we will conclude that no impairment has occurred.
Detailed impairment testing involves comparing the fair value of our one reporting unit to its carrying value, including goodwill. If the fair value exceeds carrying value, then it is concluded that no goodwill impairment has occurred. If the carrying value of the reporting unit exceeds its fair value, a second step is required to measure possible goodwill impairment loss. The second step includes hypothetically valuing the tangible and intangible assets and liabilities of our one reporting unit as if it had been acquired in a business combination. The implied fair value of our one reporting unit's goodwill then is compared to the carrying value of that goodwill. If the carrying value of our one reporting unit's goodwill exceeds the implied fair value of the goodwill, we recognize an impairment loss in an amount equal to the excess, not to exceed the carrying value.
We determined that goodwill was impaired as of September 30, 2015 and recognized a non-cash goodwill impairment charge of approximately $1.1 million to write-down the goodwill to its estimated fair value of zero as of September 30, 2015. (See Note 4 — Goodwill and Intangible Assets for additional details.)
Fair Value Measurements
The balance sheets include various financial instruments that are carried at fair value. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:
- Level 1, defined as observable inputs such as quoted prices in active markets for identical assets;
- Level 2, defined as observable inputs other than Level I prices such as quoted prices for similar assets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
- Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.
The Company remeasures to fair value its derivative liabilities at each balance sheet date. We determine the fair value of these derivative liabilities using the Black-Scholes option pricing model. When determining the fair value of our financial instruments using the Black-Scholes option pricing model, we are required to use various estimates and unobservable inputs, including, among other things, contractual terms of the instruments, expected volatility of our stock price, expected dividends, and the risk-free interest rate. Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the instrument. Increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value.
In March and June 2014, we issued stock purchase warrants and convertible notes that contained embedded conversion options; the embedded conversion options are accounted for as a derivative liability. We determine the fair value of these derivative liabilities using the binomial lattice model. When determining the fair value of our financial instruments using binomial lattice models, we also are required to use various estimates and unobservable inputs, including in addition to those listed above, the probability of certain events.
Changes in fair value are classified in “other income (expense)” in the condensed consolidated statement of operations.
Recent Accounting Pronouncements
In August 2014, the FASB issued guidance for the disclosure of uncertainties about an entity’s ability to continue as a going concern. Under U.S. GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Previously, there was no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. This was issued to provide guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We are currently evaluating the impact, if any, that the adoption will have on our consolidated financial statements.
In May 2014, the FASB issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The FASB approved a one-year deferral in July 2015, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. We are currently evaluating the impact, if any, that this new accounting pronouncement will have on our financial statements.
In April 2015, the FASB issued guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The amendment is effective for reporting periods beginning after December 15, 2015 and may be applied on either a prospective or retrospective basis. Early adoption is permitted. We do not expect the adoption of this new accounting pronouncement to have a material impact on our financial statements.
In April 2015, the FASB issued guidance to simplify the balance sheet disclosure for debt issuance costs. Under the guidance, debt issuance costs related to a recognized debt liability will be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The standard is effective for reporting periods beginning after December 15, 2015 and early adoption is permitted. We intend to adopt this requirement in 2016, and currently anticipates that the impact of adoption will solely be a reclassification of our deferred financing costs from asset classification to contra-liability classification.
In July 2015, the FASB issued guidance for the accounting of inventory. The main provisions are that an entity should measure inventory within the scope of this update at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the Board has amended some of the other guidance in Topic 330 to more clearly articulate the requirements for the measurement and disclosure of inventory. The amendments in this update for public business entities are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact, if any, that the adoption will have on our financial statements.
In September 2015, the FASB issued accounting guidance to simplify the accounting for measurement period adjustments resulting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The standard is effective for reporting periods beginning after December 15, 2015. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.
We have evaluated all other issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our results of operations, financial position, or cash flows.
Market risk
As filed, 264 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Except for matters described in Note 5 and Note 10 of the financial statements, there have been no defaults in the payment of principal, interest, sinking or purchase fund installment, or any other material default, with respect to any indebtedness of the Company.
Controls and procedures
As filed, 2,822 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (the “Certifying Officers”), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Report. Based on that evaluation, the Certifying Officers concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.
Changes in Internal Control Over Financial Reporting
Management has identified changes in our internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during 2015, which have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting, including the resignation of our Chief Financial Officer during the second quarter of 2015 and the implementation of a new financial accounting system. We are in the process of completing but have not yet completed our internal documentation of all the changes in our internal controls over financial reporting.
To specifically address the changes identified in our internal controls over financial reporting as of September 30, 2015, David E. Jorden relinquished his role as Executive Chairman of the Board and transitioned to Acting Chief Financial Officer of the Company, a role which he officially assumed effective as of May 25, 2015. In addition, we developed and performed additional analytical and substantive procedures during our quarter closing process. Management believes that these additional procedures provide reasonable assurance that our condensed consolidated financial statements as of and for the nine months ended September 30, 2015, are fairly stated in all material respects in accordance with U.S. GAAP.
Inherent Limitations on Disclosure Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
PART II
OTHER INFORMATION
Risk factors
As filed, 4,930 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Except for certain updates set forth below, there are no material changes from the risk factors as previously disclosed in our Annual Report on Form 10-K filed with the SEC on March 31, 2015 for the year ended December 31, 2014 and the Company’s subsequent filings with the SEC.
Our inability to negotiate modifications to the existing Deerfield Facility Agreement that are favorable to us will create substantial doubt regarding our ability to continue as a going concern.
As of September 30, 2015, we had approximately $4.1 million in cash and cash equivalents. Pursuant to the terms of the Deerfield Facility Agreement, prior to its temporary modification, we were required to maintain cash on deposit, subject to control agreements in favor of the Deerfield lenders, of not less than $5.0 million. As of September 30, 2015, we were not in compliance with that covenant, resulting in a technical failure to satisfy the covenant and an event of default under the Deerfield Facility Agreement. In addition, the terms of the Deerfield Facility Agreement required us to pay Deerfield the accrued interest amount of approximately $2.6 million on October 1, 2015, which we were unable to do. Subject to the terms of the modification agreements we were, and continue to be, required to make the October 1, 2015 interest payment in cash, as our ability to pay in freely tradable shares of our common stock is contingent upon, among others, no default occurring or continuing under Deerfield Facility Agreement, our market capitalization not being less than $50 million, and our common stock closing at not less than $0.35 per share, on the last trading day prior to the date of our notice electing to pay such interest in common stock. Our inability to maintain sufficient cash on deposit and make the required interest payment when due resulted in the occurrence of events default under the Deerfield Facility Agreement. As a result, Deerfield may declare the principal, including accrued and unpaid interest, on, all of the notes or any part of any of them, immediately due and payable by providing written notice to us as of December 4, 2015 for failure to maintain sufficient cash on deposit accounts or to pay interest when due, or prior thereto for any other event of default thereunder. As of the date of this filing, Deerfield has not declared a default under the Deerfield Facility Agreement. In addition, because our revenue for the three month period ended September 30, 2015 was less than the net sales threshold contemplated in the Deerfield Facility Agreement, Deerfield has the option of requiring us to prepay on March 31, 2016, an amount equal to one-third of the aggregate amount of the credit facility together with accrued and unpaid interest thereon.
On November 11, 2015, we entered into a letter agreement with Deerfield and certain of its affiliates pursuant to which the Deerfield Facility Agreement was modified to provide that, (i) between November 11, 2015 and December 4, 2015, the amount of cash that is required to be maintained in a deposit account subject to control agreements in favor of our senior lenders was reduced from $5,000,000 to $1,750,000 and (ii) the date for payment of the accrued interest amount originally payable on October 1, 2015 was extended to December 4, 2015. We believe the modification agreement will allow us to continue our substantive discussions with the lenders to reduce our risk of default, thereby permitting us to continue our operations, but we can provide no assurance that we will be successful in this effort. We cannot provide any assurance that the lenders will agree to modify the Deerfield Facility Agreement, whether any proposed modifications to the agreement would be on terms favorable, or acceptable, to us, or whether the lenders will declare an event of default under the agreement and foreclose on our assets by enforcing their rights under our agreements with them. If we cannot agree on additional modifications to the Deerfield Facility Agreement, we may be required to curtail or cease operations or, alternatively, seek court supervised protection from creditor claims. Even if we can reach an agreement to further modify the Deerfield Facility Agreement in a manner that is acceptable to us, management believes that we will be required to identify additional sources of capital in the near term to continue our operations beyond January 2016. Any additional agreement that we reach with the lenders under the Deerfield Facility Agreement is expected to involve substantial dilution to the ownership interests of holders of our common stock, and could involve other conditions causing the value of our common stock to decline. Therefore, our inability to negotiate modifications to the existing Deerfield Facility Agreement that are favorable to us will create substantial doubt regarding our ability to continue as a going concern.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-07-01 to 2015-09-30 | $2.2m | us-gaap:Revenues |
| Revenue | 9 months2015-01-01 to 2015-09-30 | $9.9m | us-gaap:Revenues |
| Cost of revenue | 3 months2015-07-01 to 2015-09-30 | $1.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2015-01-01 to 2015-09-30 | $6.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2015-07-01 to 2015-09-30 | $569.1k | us-gaap:GrossProfit |
| Gross profit | 9 months2015-01-01 to 2015-09-30 | $3.1m | us-gaap:GrossProfit |
| Research and development | 3 months2015-07-01 to 2015-09-30 | $515.2k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2015-01-01 to 2015-09-30 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-07-01 to 2015-09-30 | −$27.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2015-01-01 to 2015-09-30 | −$35.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2015-07-01 to 2015-09-30 | $4.9k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2015-01-01 to 2015-09-30 | $14.7k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-07-01 to 2015-09-30 | −$13.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2015-01-01 to 2015-09-30 | −$10.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-07-01 to 2015-09-30 | −$0.11 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2015-01-01 to 2015-09-30 | −$0.08 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2015-01-01 to 2015-09-30 | −$11.7m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months2015-01-01 to 2015-09-30 | $270.8k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-09-30 | $4.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-09-30 | $12.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-09-30 | $19.2m | us-gaap:Assets |
| Current liabilities | At period end2015-09-30 | $11.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-09-30 | $13.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-09-30 | $5.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-15-064917. Last ingested by Listed: Nov 14, 2026, 23:44 ET. Listed shows no prices and gives no investment advice.